Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., February 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NTLA) - a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, announced that on February 1, 2026, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan as a material inducement . . .